Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Reexamination Certificate
2005-02-15
2005-02-15
Criares, Theodore J. (Department: 1617)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
C424S426000, C424S457000, C424S468000, C424S501000
Reexamination Certificate
active
06855331
ABSTRACT:
A controlled release microcapsulate pharmaceutical formulation for burst-free, sustained, programmable release of hydrophobic bioactive agent over a duration from 24 hours to 100 days comprising: and a blend of end-capped uncapped biocompatible, biodegradable poly(lactide/glycolide).
REFERENCES:
patent: 3540444 (1970-11-01), Moreland
patent: 3773919 (1973-11-01), Boswell
patent: 3788315 (1974-01-01), Laurens
patent: 4166800 (1979-09-01), Fong
patent: 4384975 (1983-05-01), Fong
patent: 4530840 (1985-07-01), Tice et al.
patent: 4542025 (1985-09-01), Tice et al.
patent: 4585482 (1986-04-01), Tice et al.
patent: 4622244 (1986-11-01), Lapka et al.
patent: 4637905 (1987-01-01), Gardner
patent: 4675189 (1987-06-01), Kent et al.
patent: 4798786 (1989-01-01), Tice et al.
patent: 4835139 (1989-05-01), Tice et al.
patent: 4863735 (1989-09-01), Kohn et al.
patent: 4897268 (1990-01-01), Tice et al.
patent: 4938763 (1990-07-01), Dunn et al.
patent: 4941880 (1990-07-01), Burns
patent: 5000886 (1991-03-01), Lawter et al.
patent: 5019096 (1991-05-01), Fox, Jr. et al.
patent: 5059187 (1991-10-01), Sperry et al.
patent: 5064413 (1991-11-01), McKinnon et al.
patent: 5075109 (1991-12-01), Tice et al.
patent: 5102872 (1992-04-01), Singh et al.
patent: 5129825 (1992-07-01), Discko, Jr.
patent: 5133701 (1992-07-01), Han
patent: 5236355 (1993-08-01), Brizzolara et al.
patent: 5278202 (1994-01-01), Dunn et al.
patent: 5290494 (1994-03-01), Coombes et al.
patent: 5360610 (1994-11-01), Tice et al.
patent: 5384133 (1995-01-01), Boyes et al.
patent: 5407609 (1995-04-01), Tice et al.
patent: 5417986 (1995-05-01), Reid et al.
patent: 5429822 (1995-07-01), Gresser et al.
patent: 5648096 (1997-07-01), Gander et al.
patent: 5650173 (1997-07-01), Ramstack et al.
patent: 5705197 (1998-01-01), Van Hamont et al.
patent: 6447796 (2002-09-01), Vook et al.
patent: 0052510 (1994-10-01), None
Gilding, Biodegradable polymers for use in surgery-polyglycolic/poly (ac c acid) homo- and copolymers: 1, Polymer, vol. 20, Dec. 1979, pp1459-1464.
Biotechnology News, Aug. 22, 1997, vol. 17, No. 20, Topical DNA vaccine elicits immune response.
Hall, et al., Purification and Analysis of Colonization Factor Antigen 1, Coli Surface Antigen 1, and Coli Surface ANtigen 3 Fimbriac from EnterotoxigenicEscherichia coli, Journal of Bacteriology, Nov. 1989, p6372-6374, vol. 171, No. 11.
Evans, et al. Purification and Characterization of the CFR/I Antigen of EnterotoxigenicEscherichia coli, Infection and Immunity, Aug. 1979, p 738-748, vol. 25.
Karjalainen, et al., Molecular Cloning and Nucleotide Sequence of the Colonization Factor Antigen I Gene ofEscherichia coil, Infection and Immunity, Apr. 1989, p1126-1130, vol. 57.
Jeyanthl, et al., Novel, Burst Free Programmable Biodegradable Microspheres For Controlled Release of Polypeptides, Proceedings Int. Symp. control Release Bioact. Mater. (1996) p351-352/.
Yeh, A novel emulsification-solvent extraction technique for production of protein loaded biodegradable microparticles for vaccine and drug delivery, Journal of Controlled Release, 33 (1995) 437-445.
Yan, Characterization and morphological analysis of protein-loaded poly(lactide-co-glycolide) microparticles prepared by watewr-in-oil-in-water emulsion technique, Journal of Controlled Release, 32 (1994) 231-241.
Wang, et al., Influence of formulation methods on the in vitro controlled release of protein from poly (ester) microspheres Journal of Controlled Release, 17 (1991) 23-32.
Brown, Wonder Drugs' Losing Healing Aura, The Washing Post, Jun. 26, 1995, A section.
Setterstrom, Controlled Release of Antibiotics From biodegradable Microcapsules For Wound infection Control, Chemical Abstracts, 1983, pp215-226.
Perez-Casal, et al., Gene Encoding the Major Subunit of CS1 Pili of Human EnterotoxigenicEscherichia coli, Infection and Immunity, Nov., 1990, p 3594-3600, vol. 58, No. 11.
Jordi, et al., Analysis of the first two genes of the CS1 fimbrial operon in human entertoxigenicEscherichia coliof serotype 0139: H28, FEMS Microbiology Letters 80, (1991) p265-270.
Tan, et al., Mapping the Antigenic Epitopes of Human Dihydrofolate Reductase by Systematic Synthesis of Peptides on solid Supports, The Journal of Biological Chemistry, vol. 265, No. 14, Issue of May 15, pp. 8022-8026 (1990).
McConnel, et al., Antigenic homology within human enterotoxigenicEsherichia colifimbrial colonization factor antigens: CFA/I, coil-surface-associated antigens (CS)1, CS2, CS4 and CS17, FEMS Microbiology Letters 61 (1989) 105-108.
Van der Zee, Efficient mapping and characterization of a T cell epitope by the simultaneous synthesis of multiple peptides, Eur. J. Immunol. 1989, 19: 43-47.
Cassels, et al., Analysis ofEscherichia coliColonization Factor Antigen I Linear B-Cell Epitopes, as Determined by Primate Responses, following Protein Sequence Verification, Infection and Immunity, Jun. 1992, p. 2174-2181, vol. 60, No. 6.
Romagnoli, et al. Peptide-MHC Interaction: A Rational Approach to Vaccine Design, Inter, RE. Immunol. 6, 1990, 00 61-73.
Maister, First Oral AIDS Vaccine Trials Near, BioWorld Today, Tuesday, Apr. 19, 1994, p. 4.
Rognan, et al., Molecular Modeling of an Antigenic Complex Between a Viral Peptide and a Class I Major Histocompatibility Glycoprotein, Proteins Structure, Function and Genetics 13 70-85 (1992).
Brown, A hypothetical model of the foreign antigen blinding site of Class II histocompatibility molecules, Nature, vol. 332, Apr. 28, 1988, p845-850.
Duong Ha
Jacob Elliott
Setterstrom Jean A.
van Hamont John
Vaughan William
Arwine Elizabeth
Criares Theodore J.
The United States of America as represented by the Secretary of
LandOfFree
Sustained release hydrophobic bioactive PLGA microspheres does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sustained release hydrophobic bioactive PLGA microspheres, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sustained release hydrophobic bioactive PLGA microspheres will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3498644